^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Xcytrin (motexafin gadolinum)

    i
    Associations
    News

    Trials

    Company:
    AbbVie
    Drug class:
    Ribonucleotide reductase inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    MRI for Detecting Cancer in Women Who Are at High Risk of Developing Breast Cancer (NCT00003736)
    Phase N/A
    Abramson Cancer Center of the University of Pen...
    Completed
    Last update posted :
    09/24/2019
    Initiation :
    06/01/1999
    Primary completion :
    06/01/2002
    Completion :
    06/01/2002
    BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Xcytrin (motexafin gadolinum)